Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018

Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018

Abstract To identify the prevalence of C. auris in Canadian patients who are potentially at risk for colonization, we screened 488 patients who were either hospitalized abroad, had a carbapenemase-producing organism (CPO), or were in units with high antifungal use. Two patients were colonized with C...

Full description

Bibliographic Details
Main Authors: Hector Felipe Garcia-Jeldes, Robyn Mitchell, Allison McGeer, Wallis Rudnick, Kanchana Amaratunga, Snigdha Vallabhaneni, Shawn R. Lockhart, CNISP C. auris Interest Group, Amrita Bharat
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Antimicrobial Resistance and Infection Control
Subjects:
Candida
Cross infection
Drug resistance
Risk factors
Online Access:http://link.springer.com/article/10.1186/s13756-020-00752-3
id doaj-fb1535eb7a9a4101bbe38e75052ee498
record_format Article
spelling doaj-fb1535eb7a9a4101bbe38e75052ee4982020-11-25T03:10:49ZengBMCAntimicrobial Resistance and Infection Control2047-29942020-06-01911510.1186/s13756-020-00752-3Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018Hector Felipe Garcia-Jeldes0Robyn Mitchell1Allison McGeer2Wallis Rudnick3Kanchana Amaratunga4Snigdha Vallabhaneni5Shawn R. Lockhart6CNISP C. auris Interest GroupAmrita Bharat7CHU de Québec-Université LavalPublic Health Agency of CanadaMount Sinai HospitalPublic Health Agency of CanadaPublic Health Agency of CanadaUS Centers for Disease Control and PreventionUS Centers for Disease Control and PreventionNational Microbiology Laboratory, Public Health Agency of CanadaAbstract To identify the prevalence of C. auris in Canadian patients who are potentially at risk for colonization, we screened 488 patients who were either hospitalized abroad, had a carbapenemase-producing organism (CPO), or were in units with high antifungal use. Two patients were colonized with C. auris; both had received healthcare in India and had a CPO. Among 35 patients who had recently received healthcare in the Indian subcontinent and were CPO colonized or infected, the prevalence of C. auris was 5.7%.http://link.springer.com/article/10.1186/s13756-020-00752-3CandidaCross infectionDrug resistanceRisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Hector Felipe Garcia-Jeldes
Robyn Mitchell
Allison McGeer
Wallis Rudnick
Kanchana Amaratunga
Snigdha Vallabhaneni
Shawn R. Lockhart
CNISP C. auris Interest Group
Amrita Bharat
spellingShingle Hector Felipe Garcia-Jeldes
Robyn Mitchell
Allison McGeer
Wallis Rudnick
Kanchana Amaratunga
Snigdha Vallabhaneni
Shawn R. Lockhart
CNISP C. auris Interest Group
Amrita Bharat
Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
Antimicrobial Resistance and Infection Control
Candida
Cross infection
Drug resistance
Risk factors
author_facet Hector Felipe Garcia-Jeldes
Robyn Mitchell
Allison McGeer
Wallis Rudnick
Kanchana Amaratunga
Snigdha Vallabhaneni
Shawn R. Lockhart
CNISP C. auris Interest Group
Amrita Bharat
author_sort Hector Felipe Garcia-Jeldes
title Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
title_short Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
title_full Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
title_fullStr Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
title_full_unstemmed Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
title_sort prevalence of candida auris in canadian acute care hospitals among at-risk patients, 2018
publisher BMC
series Antimicrobial Resistance and Infection Control
issn 2047-2994
publishDate 2020-06-01
description Abstract To identify the prevalence of C. auris in Canadian patients who are potentially at risk for colonization, we screened 488 patients who were either hospitalized abroad, had a carbapenemase-producing organism (CPO), or were in units with high antifungal use. Two patients were colonized with C. auris; both had received healthcare in India and had a CPO. Among 35 patients who had recently received healthcare in the Indian subcontinent and were CPO colonized or infected, the prevalence of C. auris was 5.7%.
topic Candida
Cross infection
Drug resistance
Risk factors
url http://link.springer.com/article/10.1186/s13756-020-00752-3
work_keys_str_mv AT hectorfelipegarciajeldes prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT robynmitchell prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT allisonmcgeer prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT wallisrudnick prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT kanchanaamaratunga prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT snigdhavallabhaneni prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT shawnrlockhart prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT cnispcaurisinterestgroup prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
AT amritabharat prevalenceofcandidaaurisincanadianacutecarehospitalsamongatriskpatients2018
_version_ 1724657212805087232

Similar Items